Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
08 Agosto 2023 - 5:22PM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing targeted
radiotherapeutics with advanced platform technologies for central
nervous system cancers, today announced a key opinion leader
roundtable discussion to be held on Friday, August 11, 2023, 8:00
a.m. – 9:00 a.m. ET to discuss the latest data from the ReSPECT-LM
clinical trial of rhenium (186Re) obisbemeda that will be presented
at the Society for Neuro Oncology (SNO)/American Society of
Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer
Conference on August 10, 2023.
The webinar will feature a comprehensive
discussion about the ongoing ReSPECT-LM Phase 1/2a dose escalation
clinical trial, including key safety, tolerability, dosing,
feasibility and efficacy data. Speakers include:
- Andrew J. Brenner, M.D., Ph.D.,
Professor of Medicine, Neurology, and Neurosurgery at The
University of Texas, Health Services Center at San Antonio and
principal investigator of the ReSPECT-GBM trial and co-principal
investigator of the ReSPECT-LM trial.
- Priya Kumthekar, M.D., Associate
Professor of Neurology and Medicine (Hematology and Oncology) at
Northwestern University’s Feinberg School of Medicine and
co-principal investigator of the ReSPECT-LM trial.
- Marc H. Hedrick, M.D., President
and Chief Executive Officer of Plus Therapeutics
- Justin Walsh, Ph.D., Senior
Healthcare Analyst, Jones Research will moderate the roundtable and
in addition will provide an overview of the radiotherapeutic
market.
Webcast Details
A webinar with accompanying slides will be
available in the Events page of the Investor Relations section of
the Plus Therapeutics website beginning Friday, August 11, 2023 at
8:00 a.m. ET. Participants may also pre-register any time before
the call here. Please access the webinar 15 minutes prior to the
start time.
The webinar will be available on the Company’s
website under the 'For Investor' section. The webcast will be
available on the Company’s website for 90 days following the live
call.
About Plus TherapeuticsPlus
Therapeutics, Inc. is a clinical-stage pharmaceutical company
developing targeted radiotherapeutics for difficult-to-treat
cancers of the central nervous system with the potential to enhance
clinical outcomes for patients. Combining image-guided local beta
radiation and targeted drug delivery approaches, the Company is
advancing a pipeline of product candidates with lead programs in
recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
The Company has built a robust supply chain through strategic
partnerships that enable the development, manufacturing and future
potential commercialization of its products. Plus Therapeutics is
led by an experienced and dedicated leadership team and has
operations in key cancer clinical development hubs including Austin
and San Antonio, Texas. For more information, visit
https://plustherapeutics.com/ and https://respect-trials.com.
Cautionary Statement Regarding
Forward-Looking StatementsThis press release contains
statements that may be deemed “forward-looking statements” within
the meaning of U.S. securities laws. All statements in this press
release other than statements of historical fact are
forward-looking statements. These forward-looking statements may be
identified by future verbs, as well as terms such as “designed to,”
“will,” “can,” “potential,” “focus,” “preparing,” “next steps,”
“possibly,” and similar expressions or the negatives thereof. Such
statements are based upon certain assumptions and assessments made
by management in light of their experience and their perception of
historical trends, current conditions, expected future developments
and other factors they believe to be appropriate. These statements
include, without limitation, statements regarding the following:
the potential promise of 186Re including the ability of 186Re to
safely and effectively deliver radiation directly to the tumor at
high doses; expectations as to the Company’s future performance
including the next steps in developing the Company’s current
assets; the Company’s clinical trials including statements
regarding the timing and characteristics of the ReSPECT-GBM and
ReSPECT-LM clinical trials; possible negative effects of 186Re; the
continued evaluation of 186Re including through evaluations in
additional patient cohorts; and the intended functions of the
Company’s platform and expected benefits from such functions.
The forward-looking statements included in this
press release are subject to a number of risks and uncertainties
that may cause actual results to differ materially from those
discussed in such forward-looking statements. These risks and
uncertainties include, but are not limited to: the Company’s actual
results may differ, including materially, from those anticipated in
these forward-looking statements as a result of various factors,
including, but not limited to, the following: the early stage of
the Company’s product candidates and therapies, the results of the
Company’s research and development activities, including
uncertainties relating to the clinical trials of its product
candidates and therapies; the Company’s liquidity and capital
resources and its ability to raise additional cash, the outcome of
the Company’s partnering/licensing efforts, risks associated with
laws or regulatory requirements applicable to it, market
conditions, product performance, litigation or potential
litigation, and competition within the cancer diagnostics and
therapeutics field, among others; and additional risks described
under the heading “Risk Factors” in the Company’s Securities and
Exchange Commission filings, including in the Company’s annual and
quarterly reports. There may be events in the future that the
Company is unable to predict, or over which it has no control, and
its business, financial condition, results of operations and
prospects may change in the future. The Company assumes no
responsibility to update or revise any forward-looking statements
to reflect events, trends or circumstances after the date they are
made unless the Company has an obligation under U.S. federal
securities laws to do so.
Investor ContactPeter VozzoICR Westwicke(443)
377-4767Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerICR Westwicke(203)
856-4326Terri.Clevenger@westwicke.com
Grafico Azioni Plus Therapeutics (NASDAQ:PSTV)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Plus Therapeutics (NASDAQ:PSTV)
Storico
Da Lug 2023 a Lug 2024